Charles River board approves appointment of four new directors

Charles River (CRL) Laboratories announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company’s business focused on enhancing long-term value for shareholders. Charles River’s Board of Directors has agreed to appoint four new directors, Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves, who will join the Board effective following the 2025 Annual Meeting of Shareholders to be held on May 20, 2025. Four existing directors, Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman, have announced their intentions to not seek re-election at the end of their previously elected terms at the 2025 Annual Meeting. Following the new director appointments, the Company’s Board will consist of eleven directors, nine of whom will be independent. As part of these actions, Martin Mackay, Ph.D. will serve as Lead Independent Director, Nancy Andrews, M.D., Ph.D. will serve as Chair of the Corporate Governance and Nominating Committee, and Reshema Kemps-Polanco will serve as Chair of the Compensation Committee. Virginia Wilson will remain Chair of the Audit Committee. Additionally, Steven Barg, Mark Enyedy and Paul Graves will join the Strategic Planning and Capital Allocation Committee, with Paul Graves serving as Chair. The Board will also establish a New Approach Methodologies and Science Committee through the combination of the Science and Technology and Responsible Animal Use committees, which will be chaired by Craig Thompson, M.D. The Board, through the Strategic Planning and Capital Allocation Committee, will conduct a comprehensive strategic review and evaluation of Charles River’s business and prospects, including an examination of various alternatives to enhance long-term stockholder value. The committee will present its recommendations to the full Board upon completion of its review.